Spark Therapeutics Inc (NASDAQ:ONCE) was the target of some unusual options trading activity on Wednesday. Investors bought 1,788 put options on the stock. This represents an increase of 1,636% compared to the typical volume of 103 put options.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of Spark Therapeutics by 5.5% during the second quarter. Vanguard Group Inc. now owns 3,177,757 shares of the biotechnology company’s stock worth $325,338,000 after buying an additional 166,399 shares during the last quarter. CNH Partners LLC bought a new stake in shares of Spark Therapeutics during the first quarter worth $89,851,000. Alpine Associates Management Inc. grew its stake in shares of Spark Therapeutics by 13.3% during the second quarter. Alpine Associates Management Inc. now owns 784,100 shares of the biotechnology company’s stock worth $80,277,000 after buying an additional 91,800 shares during the last quarter. Paulson & CO. Inc. bought a new stake in shares of Spark Therapeutics during the second quarter worth $77,584,000. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Spark Therapeutics by 0.3% during the second quarter. Price T Rowe Associates Inc. MD now owns 694,696 shares of the biotechnology company’s stock worth $71,123,000 after buying an additional 2,381 shares during the last quarter. 81.40% of the stock is currently owned by hedge funds and other institutional investors.
ONCE has been the subject of several research analyst reports. Mizuho restated a “hold” rating and set a $114.50 price objective on shares of Spark Therapeutics in a research report on Monday, August 12th. Zacks Investment Research downgraded shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $87.92.
About Spark Therapeutics
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.
Featured Story: Convertible Shares
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.